Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-28

Elanco Animal Health Inc (ELAN)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$14,925,756
Jeffrey Simmons total, FY2025
44th
CEO pay percentile vs peers
181:1
CEO-to-median pay ratio
82%
Say-on-pay support, latest vote
Companies that benchmark against ELAN
5 companies name ELAN as a compensation peer

Each company listed discloses ELAN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ELAN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jeffrey Simmons$1,200,000$0$9,000,000$3,000,004$1,700,400$0$25,352$14,925,756
President and Chief Executive Officer
Todd Young477,09602,175,000725,004001,377,7894,754,889
Former Executive Vice President and Chief Financial Officer
Robert VanHimbergen317,308890,0002,285,026550,002539,550079,4194,661,304
Executive Vice President and Chief Financial Officer
Ellen de Brabander847,82901,716,010572,003739,307036,0813,911,229
Executive Vice President, Innovation and Regulatory Affairs
Ramiro Cabral650,00001,500,011500,003566,800026,9523,243,767
Executive Vice President, President International
Timothy Bettington656,00001,050,020350,005500,528026,9522,583,505
Executive Vice President, Center for Strategic Growth

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Jeffrey Simmons$14,925,756$14,833,704$13,663,169+92,052
Todd Young4,754,8894,109,3613,726,720+645,528
Robert VanHimbergen4,661,304
Ellen de Brabander3,911,2293,913,9323,683,732−2,703
Ramiro Cabral3,243,7672,942,4712,650,754+301,296
Timothy Bettington2,583,5052,533,3892,053,962+50,116

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Dividend-equivalent accruals2026-04-17190~4,5013 insiders, 3 accrual rows
Dividend-equivalent accruals2026-05-01200~4,5013 insiders, 3 accrual rows
Dividend-equivalent accruals2026-05-15227~4,5013 insiders, 3 accrual rows
Jeffrey SimmonsDirector2026-05-15A4,9712099,843CommonForm 4 ↗
Rajeev A. ModiSEE REMARKS2026-05-15A4,9112099,939CommonForm 4 ↗
Paul HerendeenDirector2026-05-21A4,67800CommonForm 4 ↗
R. David HooverDirector2026-05-21A4,67800CommonForm 4 ↗
Michael HarringtonDirector2026-05-21A4,67800CommonForm 4 ↗
Denise Scots-KnightDirector2026-05-21A12,19600CommonForm 4 ↗
Lawrence KurziusDirector2026-05-21A4,67800CommonForm 4 ↗
Lawrence KurziusDirector2026-05-21A12,19600CommonForm 4 ↗
Kirk McDonaldDirector2026-05-21A4,67800CommonForm 4 ↗
Deborah KochevarDirector2026-05-21A4,67800CommonForm 4 ↗
Stacey MaDirector2026-05-21A12,19600CommonForm 4 ↗
Michael HarringtonDirector2026-05-21A12,19600CommonForm 4 ↗
Kirk McDonaldDirector2026-05-21A12,19600CommonForm 4 ↗
Paul HerendeenDirector2026-05-21A12,19600CommonForm 4 ↗
Art GarciaDirector2026-05-21A12,19600CommonForm 4 ↗
Denise Scots-KnightDirector2026-05-21A4,67800CommonForm 4 ↗
Art GarciaDirector2026-05-21A4,67800CommonForm 4 ↗
Stacey MaDirector2026-05-21A4,67800CommonForm 4 ↗
Kapila AnandDirector2026-05-21A12,19600CommonForm 4 ↗
Kapila AnandDirector2026-05-21A4,67800CommonForm 4 ↗
Dividend-equivalent accruals2026-05-29189~4,5013 insiders, 3 accrual rows
Dividend-equivalent accruals2026-06-12186~4,5013 insiders, 3 accrual rows
Dividend-equivalent accruals2026-06-26183~4,5013 insiders, 3 accrual rows
Kapila AnandDirector2026-06-30A584.112514,375Derivative, Class A CommonForm 4 ↗
David S. KinardSEE REMARKS2026-07-01A25,62000Derivative, Class A CommonForm 4 ↗
Robert VanHimbergenEVP and CFO2026-07-07D15,33625377,879CommonForm 4 ↗
Dividend-equivalent accruals2026-07-10181~4,5013 insiders, 3 accrual rows
Dividend-equivalent accruals2026-07-24181~4,5013 insiders, 3 accrual rows

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 47 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Rajeev A. ModiSEE REMARKS2026-04-17A62.37$24$1,477Derivative, Class A CommonForm 4 ↗
Robert VanHimbergenEVP and CFO2026-04-17A8.3224197Derivative, Class A CommonForm 4 ↗
Jeffrey SimmonsDirector2026-04-17A119.38242,827Derivative, Class A CommonForm 4 ↗
Jeffrey SimmonsDirector2026-05-01A125.59232,827Derivative, Class A CommonForm 4 ↗
Rajeev A. ModiSEE REMARKS2026-05-01A65.61231,477Derivative, Class A CommonForm 4 ↗
Robert VanHimbergenEVP and CFO2026-05-01A8.7523197Derivative, Class A CommonForm 4 ↗
Rajeev A. ModiSEE REMARKS2026-05-15A74.37201,477Derivative, Class A CommonForm 4 ↗
Robert VanHimbergenEVP and CFO2026-05-15A9.9220197Derivative, Class A CommonForm 4 ↗
Jeffrey SimmonsDirector2026-05-15A142.34202,827Derivative, Class A CommonForm 4 ↗
Jeffrey SimmonsDirector2026-05-15A4,9712099,843CommonForm 4 ↗
Rajeev A. ModiSEE REMARKS2026-05-15A4,9112099,939CommonForm 4 ↗
Paul HerendeenDirector2026-05-21A4,67800CommonForm 4 ↗
R. David HooverDirector2026-05-21A4,67800CommonForm 4 ↗
Michael HarringtonDirector2026-05-21A4,67800CommonForm 4 ↗
Denise Scots-KnightDirector2026-05-21A12,19600CommonForm 4 ↗
Lawrence KurziusDirector2026-05-21A4,67800CommonForm 4 ↗
Lawrence KurziusDirector2026-05-21A12,19600CommonForm 4 ↗
Kirk McDonaldDirector2026-05-21A4,67800CommonForm 4 ↗
Deborah KochevarDirector2026-05-21A4,67800CommonForm 4 ↗
Stacey MaDirector2026-05-21A12,19600CommonForm 4 ↗
Michael HarringtonDirector2026-05-21A12,19600CommonForm 4 ↗
Kirk McDonaldDirector2026-05-21A12,19600CommonForm 4 ↗
Paul HerendeenDirector2026-05-21A12,19600CommonForm 4 ↗
Art GarciaDirector2026-05-21A12,19600CommonForm 4 ↗
Denise Scots-KnightDirector2026-05-21A4,67800CommonForm 4 ↗
Art GarciaDirector2026-05-21A4,67800CommonForm 4 ↗
Stacey MaDirector2026-05-21A4,67800CommonForm 4 ↗
Kapila AnandDirector2026-05-21A12,19600CommonForm 4 ↗
Kapila AnandDirector2026-05-21A4,67800CommonForm 4 ↗
Jeffrey SimmonsDirector2026-05-29A118.53242,827Derivative, Class A CommonForm 4 ↗
Robert VanHimbergenEVP and CFO2026-05-29A8.2624197Derivative, Class A CommonForm 4 ↗
Rajeev A. ModiSEE REMARKS2026-05-29A61.93241,477Derivative, Class A CommonForm 4 ↗
Jeffrey SimmonsDirector2026-06-12A116.96242,827Derivative, Class A CommonForm 4 ↗
Rajeev A. ModiSEE REMARKS2026-06-12A61.11241,477Derivative, Class A CommonForm 4 ↗
Robert VanHimbergenEVP and CFO2026-06-12A8.1524197Derivative, Class A CommonForm 4 ↗
Rajeev A. ModiSEE REMARKS2026-06-26A60.11251,477Derivative, Class A CommonForm 4 ↗
Robert VanHimbergenEVP and CFO2026-06-26A8.0225197Derivative, Class A CommonForm 4 ↗
Jeffrey SimmonsDirector2026-06-26A115.06252,827Derivative, Class A CommonForm 4 ↗
Kapila AnandDirector2026-06-30A584.112514,375Derivative, Class A CommonForm 4 ↗
David S. KinardSEE REMARKS2026-07-01A25,62000Derivative, Class A CommonForm 4 ↗
Robert VanHimbergenEVP and CFO2026-07-07D15,33625377,879CommonForm 4 ↗
Rajeev A. ModiSEE REMARKS2026-07-10A59.51251,477Derivative, Class A CommonForm 4 ↗
Robert VanHimbergenEVP and CFO2026-07-10A7.9425197Derivative, Class A CommonForm 4 ↗
Jeffrey SimmonsDirector2026-07-10A113.9252,827Derivative, Class A CommonForm 4 ↗
Rajeev A. ModiSEE REMARKS2026-07-24A59.29251,477Derivative, Class A CommonForm 4 ↗
Robert VanHimbergenEVP and CFO2026-07-24A7.9125197Derivative, Class A CommonForm 4 ↗
Jeffrey SimmonsDirector2026-07-24A113.49252,827Derivative, Class A CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Todd YoungOPTION2025-03-03134,509$725,004
Robert VanHimbergenOTHER2025-10-018550,002
Ramiro CabralPSU2025-03-0388,418176,8361,000,008
Jeffrey SimmonsOPTION2025-03-03556,5873,000,004
Jeffrey SimmonsRSU2025-03-03265,2523,000,000
Ramiro CabralRSU2025-03-0344,209500,004
Timothy BettingtonPSU2025-03-0361,893123,786700,010
Timothy BettingtonRSU2025-03-0330,947350,011
Jeffrey SimmonsPSU2025-03-03530,5041,061,0086,000,000
Todd YoungRSU2025-03-03128,206256,412
Robert VanHimbergenRSU2025-10-0183,4141,735,011
Todd YoungRSU2025-03-0364,103725,005
Timothy BettingtonOPTION2025-03-0364,936350,005
Ramiro CabralOPTION2025-03-0392,765500,003
Robert VanHimbergenRSU2025-10-0126,443550,014
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Todd Young$981,417$0$725,0040.0%
Robert VanHimbergen2,285,025000.0%
Ramiro Cabral500,0041,000,008500,00350.0%
Jeffrey Simmons3,000,0006,000,0003,000,00450.0%
Timothy Bettington350,011700,010350,00550.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Ramiro CabralRSU18,966$429,201
Timothy BettingtonRSU14,630331,077
Timothy BettingtonRSU43,669988,229
Jeffrey SimmonsRSU374,2998,470,386
Jeffrey SimmonsRSU265,2526,002,653
Ramiro CabralOption92,76511.31
Ramiro CabralRSU56,6131,281,152
Ramiro CabralRSU44,2091,000,450
Ramiro CabralRSU12,835290,456
Jeffrey SimmonsRSU125,3912,837,598
Timothy BettingtonRSU61,8931,400,639
Robert VanHimbergenRSU63,6941,441,395
Robert VanHimbergenRSU21,338482,879
Robert VanHimbergenRSU15,416348,864
Ramiro CabralRSU88,4182,000,899
Jeffrey SimmonsOption556,58711.31
Jeffrey SimmonsOption273,47016.03
Robert VanHimbergenOption46,53616.03
Ramiro CabralOption29,31111.26
Timothy BettingtonOption31,90616.03
Robert VanHimbergenOption53,86920.8
Jeffrey SimmonsOption193,10411.26
Timothy BettingtonOption64,93611.31
Robert VanHimbergenRSU50,5751,144,512
Robert VanHimbergenOption106,12311.31
Robert VanHimbergenRSU101,1502,289,025
Robert VanHimbergenRSU34,154772,905
Robert VanHimbergenOption35,20811.26
Jeffrey SimmonsRSU530,50412,005,306
Jeffrey SimmonsRSU84,5481,913,321
Robert VanHimbergenRSU83,4141,887,659
Timothy BettingtonRSU30,947700,331
Robert VanHimbergenRSU26,443598,405
Ramiro CabralOption41,36316.03
05

Incentive-plan design — the Compensation Discussion & Analysis

To ensure that we can attract, retain, motivate and reward a leadership team that will drive long-term growth for shareholders while maintaining affordability within our business plan.

CEO STI target (% of salary)130%
CEO LTI target (% of salary)
Independent consultantWillis Towers Watson (WTW)
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-21383,528,22284,173,798253,47182%Passed
20252025-05-16244,532,049212,491,837117,02553.51%Passed
20242024-05-30409,526,32831,095,963549,79792.94%Passed
20232023-05-18351,081,26582,468,6712,251,23080.98%Passed
20222022-05-18371,016,12828,930,174142,53492.77%Passed
20212021-05-19382,057,34712,983,446250,20596.71%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2182%a
20252025-05-1653.51%b
20242024-05-3092.94%c

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “Abstentions or broker non-votes with respect to these proposals, if any, will have no effect on the outcome of the vote.”.

c. Approved under the standard stated in the filing — “Abstentions or broker non-votes with respect to these proposals, if any, will have no effect on the outcome of the vote.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)181 : 1
CEO total compensation$14,925,756
Median employee compensation$82,675
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Lawrence KurziusIndependent · Board Chair · Finance, Strategy and Oversight$240,000$240,007$0$0$0$480,007
Kirk McDonaldIndependent · Compensation and Human Capital (Chair) · Innovation, Science and Technology110,000240,007000350,007
Deborah KochevarIndependent · Corporate Governance · Innovation, Science and Technology106,000240,007000346,007
Michael HarringtonIndependent · Audit · Corporate Governance (Chair)106,000240,007000346,007
Paul HerendeenIndependent · Audit · Finance, Strategy and Oversight100,022240,007000340,029
Art GarciaIndependent · Audit · Finance, Strategy and Oversight90,000240,007000330,007
Denise Scots-KnightIndependent · Compensation and Human Capital · Innovation, Science and Technology (Chair)90,000240,007000330,007
R. David HooverIndependent · Compensation and Human Capital · Corporate Governance90,000240,007000330,007
Kapila AnandIndependent · Audit (Chair) · Corporate Governance57,500240,007000297,507
Stacey MaIndependent · Compensation and Human Capital · Innovation, Science and Technology · Newly elected12,473240,007000252,480
John BilbreyIndependent · Departed during FY39,89688,775000128,671
Craig WallaceIndependent · Departed during FY33,87488,775000122,649
Kathleen TurnerIndependent · Departed during FY33,87488,775000122,649
William DoyleIndependent · Departed during FY19,00049,33200068,332
Jeffrey SimmonsEmployee director · Finance, Strategy and Oversight00000
09

Board fee structure and ownership guideline

Annual cash retainer$90,000
Annual equity retainer$240,007
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$1,128,639
Equity awards (grant-date value)$2,715,727
All other compensation$0
Total cost of the board$3,844,366

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Elanco Animal Health Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Elanco Animal Health Inc.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Incyte Corporation2025William Meury$647,260$27,509,657$2,573,998$1,300,000$32,085,952
2Biogen Inc.2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
3Vertex Pharmaceuticals, Inc.2025Reshma Kewalramani1,600,00015,002,27004,118,64021,144,261
4Jazz Pharmaceuticals plc2025Renee Gala1,003,26916,138,43301,980,00019,151,558
5Zoetis Inc.2025Kristin Peck1,350,00010,218,5833,406,2292,187,00019,046,509
6Edwards Lifesciences Corporation2025Bernard Zovighian1,192,5007,167,0246,499,1092,406,53717,454,255
7Bausch Health Companies Inc.2025Thomas Appio1,236,00013,032,56202,336,00016,877,326
8Zimmer Biomet Holdings, Inc.2025Ivan Tornos1,281,84612,000,10102,420,76716,106,550
9Hologic, Inc.2024Stephen MacMillan1,212,6289,141,4682,937,4771,990,41315,819,261
10Charles River Laboratories International, Inc.2025James Foster1,545,63611,601,08902,182,66615,435,220
11Elanco Animal Health Inc2025Jeffrey Simmons1,200,0009,000,0003,000,0041,700,40014,925,756
12IDEXX Laboratories, Inc.2025Jonathan Mazelsky1,150,0005,399,8815,400,0012,593,00014,580,122
13Revvity, Inc.2025Prahlad R. Singh1,129,2317,694,9852,559,1522,385,45013,809,549
14Agilent Technologies, Inc.2025Padraig McDonnell1,141,3458,169,8502,017,7591,436,80912,827,236
15STERIS plc2026Daniel Carestio1,095,7074,333,9514,334,2511,725,00711,508,522
16QuidelOrtho Corporation2025Brian Blaser1,000,0008,965,82201,274,50011,255,782
17Perrigo Company plc2025Patrick Lockwood-Taylor1,223,3336,990,5640687,2509,042,603
18DENTSPLY SIRONA Inc.2025Daniel Scavilla431,7533,484,4883,221,523437,1508,760,139
19Catalent, Inc.2023Alessandro Maselli925,0003,850,2161,650,01906,583,672

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Elanco Animal Health Incnot disclosedPSU 50 · RSU 25 · Options 25NoWillis Towers Watson (WTW)
Agilent Technologies, Inc.not disclosedPSU 60 · Options 20 · RSU 20NoSemler Brossy
Bausch Health Companies Inc.126%PSU 60 · RSU 40Yes — Relative Total Shareholder Return (rTSR)Pay Governance
Biogen Inc.127%PSU 60 · RSU 40YesPay Governance
Catalent, Inc.0%PSU 50 · Options 30 · RSU 20NoFrederic W. Cook & Co., Inc.
Charles River Laboratories International, Inc.139%PSU 60 · RSU 40Yes — Three-year rTSRPay Governance
DENTSPLY SIRONA Inc.66%PSU 50 · Options 50NoFrederic W. Cook & Co., Inc.
Edwards Lifesciences Corporation127%Options 50 · PSU 25 · RSU 25NoSemler Brossy Consulting Group
Hologic, Inc.109%PSU 50 · RSU 25 · Options 25Nonot disclosed
IDEXX Laboratories, Inc.140%Options 50 · PSU 50NoFarient
Incyte Corporation138.6%PSU 60 · Options 20 · RSU 20Yes — relative total shareholder return (TSR)Aon
Jazz Pharmaceuticals plc150%PSU 50 · RSU 50Yes — Relative TSRAon
Perrigo Company plc44.3%PSU 70 · RSU 30Yes — Relative TSR (rTSR)FW Cook
QuidelOrtho Corporation127%PSU 60 · RSU 40Yes — Total Shareholder Return (TSR)Compensia
Revvity, Inc.124%PSU 50 · RSU 25 · Options 25NoPearl Meyer
STERIS plc125.1%RSU 50 · Options 50not disclosedFrederic W. Cook & Co., Inc.
Vertex Pharmaceuticals, Inc.not disclosedPSU 55 · RSU 45Nonot disclosed
Zimmer Biomet Holdings, Inc.125.9%RSU 50 · PSU 50Yes — Relative TSRSemler Brossy
Zoetis Inc.108%PSU 50 · Options 25 · RSU 25Yes — Relative TSRPearl Meyer

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

FAQ

Frequently asked questions

Who was the highest-paid executive at Elanco Animal Health Inc in fiscal 2025?
The highest-paid executive at Elanco Animal Health Inc in fiscal 2025 was Jeffrey Simmons, President and Chief Executive Officer, with total compensation of $14,925,756.
How does Elanco Animal Health Inc's chief executive pay compare to its disclosed peer group?
As disclosed, the CEO pay percentile of disclosed peers was the 44th percentile.
What is Elanco Animal Health Inc's CEO-to-median employee pay ratio?
The CEO-to-median employee pay ratio was 181:1.
How did shareholders vote on Elanco Animal Health Inc's executive compensation?
Shareholders supported the latest executive compensation proposal with 82% of votes cast.
How much does Elanco Animal Health Inc spend in total on board compensation for fiscal 2025?
The total board compensation for fiscal 2025 was $3,844,366.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Jeffrey SimmonsDEF 14A2026-04-080001739104-26-000016Section “Summary Compensation Table”. As printed: 14,925,756. Filing ↗machine: r4 · c24 · span 1067844–1067854
2Section 01, Todd YoungDEF 14A2026-04-080001739104-26-000016Section “Summary Compensation Table”. As printed: 4,754,889. Filing ↗machine: r27 · c24 · span 1111204–1111213
3Section 01, Robert VanHimbergenDEF 14A2026-04-080001739104-26-000016Section “Summary Compensation Table”. As printed: 4,661,304. Filing ↗machine: r9 · c24 · span 1077803–1077812
4Section 01, Ellen de BrabanderDEF 14A2026-04-080001739104-26-000016Section “Summary Compensation Table”. As printed: 3,911,229. Filing ↗machine: t194 · r12 · c14 · span 1082147–1082156
5Section 01, Ramiro CabralDEF 14A2026-04-080001739104-26-000016Section “Summary Compensation Table”. As printed: 3,243,767. Filing ↗machine: r17 · c24 · span 1091930–1091939
6Section 01, Timothy BettingtonDEF 14A2026-04-080001739104-26-000016Section “Summary Compensation Table”. As printed: 2,583,505. Filing ↗machine: r22 · c24 · span 1101906–1101915
7Section 03, Todd Young OPTIONDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r39 · c13 · span 1226039–1226046
8Section 03, Robert VanHimbergen OTHERDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r15 · c14 · span 1179247–1179254
9Section 03, Ramiro Cabral PSUDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r25 · c16 · span 1198239–1198248
10Section 03, Jeffrey Simmons OPTIONDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r9 · c14 · span 1167934–1167943
11Section 03, Jeffrey Simmons RSUDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r8 · c14 · span 1165333–1165342
12Section 03, Ramiro Cabral RSUDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r26 · c14 · span 1200650–1200657
13Section 03, Timothy Bettington PSUDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r31 · c16 · span 1210091–1210098
14Section 03, Timothy Bettington RSUDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r32 · c14 · span 1212500–1212507
15Section 03, Jeffrey Simmons PSUDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r7 · c16 · span 1162921–1162930
16Section 03, Todd Young RSUDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r37 · c9 · span 1220911–1220918
17Section 03, Robert VanHimbergen RSUDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r13 · c14 · span 1174316–1174325
18Section 03, Todd Young RSUDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r38 · c13 · span 1223502–1223509
19Section 03, Timothy Bettington OPTIONDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r33 · c15 · span 1215206–1215213
20Section 03, Ramiro Cabral OPTIONDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r27 · c14 · span 1203285–1203292
21Section 03, Robert VanHimbergen RSUDEF 14A2026-04-080001739104-26-000016Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r14 · c13 · span 1176750–1176757
22Section 07, pay ratioDEF 14A2026-04-080001739104-26-000016Section “CEO Pay Ratio”. As printed: 181 : 1. Filing ↗machine: span 1486950–1486953
23Section 08, Lawrence KurziusDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 480,007. Filing ↗machine: t99 · r11 · c5 · span 621552–621559
24Section 08, Kirk McDonaldDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 350,007. Filing ↗machine: t99 · r13 · c5 · span 624395–624402
25Section 08, Deborah KochevarDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 346,007. Filing ↗machine: t99 · r10 · c5 · span 620125–620132
26Section 08, Michael HarringtonDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 346,007. Filing ↗machine: t99 · r7 · c5 · span 615851–615858
27Section 08, Paul HerendeenDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 340,029. Filing ↗machine: t99 · r8 · c5 · span 617276–617283
28Section 08, Art GarciaDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 330,007. Filing ↗machine: t99 · r6 · c5 · span 614422–614429
29Section 08, Denise Scots-KnightDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 330,007. Filing ↗machine: t99 · r14 · c5 · span 625824–625831
30Section 08, R. David HooverDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 330,007. Filing ↗machine: t99 · r9 · c5 · span 618698–618705
31Section 08, Kapila AnandDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 297,507. Filing ↗machine: t99 · r3 · c5 · span 609736–609743
32Section 08, Stacey MaDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 252,480. Filing ↗machine: t99 · r12 · c5 · span 622971–622978
33Section 08, John BilbreyDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 128,671. Filing ↗machine: t99 · r4 · c5 · span 611369–611376
34Section 08, Craig WallaceDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 122,649. Filing ↗machine: t99 · r16 · c5 · span 629286–629293
35Section 08, Kathleen TurnerDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 122,649. Filing ↗machine: t99 · r15 · c5 · span 627460–627467
36Section 08, William DoyleDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 68,332. Filing ↗machine: t99 · r5 · c5 · span 613003–613009
37Section 08, Jeffrey SimmonsDEF 14A2026-04-080001739104-26-000016Section “Director Compensation”. As printed: 0. Filing ↗
38Section 02, Rajeev A. Modi 2026-04-17Form 42026-04-210001916473-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Robert VanHimbergen 2026-04-17Form 42026-04-210001724169-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Jeffrey Simmons 2026-04-17Form 42026-04-210001479079-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Jeffrey Simmons 2026-05-01Form 42026-05-050001479079-26-000023Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Rajeev A. Modi 2026-05-01Form 42026-05-050001916473-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Robert VanHimbergen 2026-05-01Form 42026-05-050001724169-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Rajeev A. Modi 2026-05-15Form 42026-05-190001916473-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Robert VanHimbergen 2026-05-15Form 42026-05-190001724169-26-000023Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Jeffrey Simmons 2026-05-15Form 42026-05-190001479079-26-000025Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Jeffrey Simmons 2026-05-15Form 42026-05-190001479079-26-000025Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Rajeev A. Modi 2026-05-15Form 42026-05-190001916473-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Paul Herendeen 2026-05-21Form 42026-05-260001374175-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, R. David Hoover 2026-05-21Form 42026-05-260001186033-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Michael Harrington 2026-05-21Form 42026-05-260001566340-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Denise Scots-Knight 2026-05-21Form 42026-05-260001297000-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Lawrence Kurzius 2026-05-21Form 42026-05-260001352090-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Lawrence Kurzius 2026-05-21Form 42026-05-260001352090-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Kirk McDonald 2026-05-21Form 42026-05-260001517740-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Deborah Kochevar 2026-05-21Form 42026-05-260001448579-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Stacey Ma 2026-05-21Form 42026-05-260001872431-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Michael Harrington 2026-05-21Form 42026-05-260001566340-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Kirk McDonald 2026-05-21Form 42026-05-260001517740-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Paul Herendeen 2026-05-21Form 42026-05-260001374175-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Art Garcia 2026-05-21Form 42026-05-260001183585-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Denise Scots-Knight 2026-05-21Form 42026-05-260001297000-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Art Garcia 2026-05-21Form 42026-05-260001183585-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Stacey Ma 2026-05-21Form 42026-05-260001872431-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Kapila Anand 2026-05-21Form 42026-05-260001679166-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Kapila Anand 2026-05-21Form 42026-05-260001679166-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Jeffrey Simmons 2026-05-29Form 42026-06-020001479079-26-000027Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Robert VanHimbergen 2026-05-29Form 42026-06-020001724169-26-000025Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Rajeev A. Modi 2026-05-29Form 42026-06-020001916473-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Jeffrey Simmons 2026-06-12Form 42026-06-160001479079-26-000029Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Rajeev A. Modi 2026-06-12Form 42026-06-160001916473-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Robert VanHimbergen 2026-06-12Form 42026-06-160001724169-26-000027Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Rajeev A. Modi 2026-06-26Form 42026-06-300001916473-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Robert VanHimbergen 2026-06-26Form 42026-06-300001724169-26-000029Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Jeffrey Simmons 2026-06-26Form 42026-06-300001479079-26-000031Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Kapila Anand 2026-06-30Form 42026-07-020001679166-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, David S. Kinard 2026-07-01Form 42026-07-020001752439-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Robert VanHimbergen 2026-07-07Form 42026-07-090001724169-26-000031Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Rajeev A. Modi 2026-07-10Form 42026-07-140001916473-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Robert VanHimbergen 2026-07-10Form 42026-07-140001724169-26-000033Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Jeffrey Simmons 2026-07-10Form 42026-07-140001479079-26-000033Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Rajeev A. Modi 2026-07-24Form 42026-07-280001916473-26-000034Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Robert VanHimbergen 2026-07-24Form 42026-07-280001724169-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Jeffrey Simmons 2026-07-24Form 42026-07-280001479079-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
85Section 06, 2026 voteForm 8-K2026-05-270001104659-26-067002Item 5.07 · say-on-pay result. As reported: 82% (votes for as printed: 383,528,222). Filing ↗
86Section 06, 2025 voteForm 8-K2025-05-210001104659-25-051136Item 5.07 · say-on-pay result. As reported: 53.51% (votes for as printed: 244,532,049). Filing ↗
87Section 06, 2024 voteForm 8-K2024-06-040001104659-24-068253Item 5.07 · say-on-pay result. As reported: 92.94% (votes for as printed: 409,526,328). Filing ↗
88Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
89Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
90Section 09b board cost (computed)ComputedcomputedCash 1,128,639 + equity 2,715,727 + all other 0 = 3,844,366, summed across the director compensation table rows.machine: formula: Σ = 3,844,366
91Incyte Corporation, Section 10b CEO totalDEF 14A2026-04-280000879169-26-000031CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
92Biogen Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187303CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391
93Vertex Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-020000875320-26-000153CEO total compensation as printed in Vertex Pharmaceuticals, Inc.'s own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809
94Jazz Pharmaceuticals plc, Section 10b CEO totalDEF 14A2026-06-080001232524-26-000029CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379
95Zoetis Inc., Section 10b CEO totalDEF 14A2026-04-080001555280-26-000015CEO total compensation as printed in Zoetis Inc.'s own proxy. As printed: 19,046,509. Filing ↗machine: r3 · c24 · span 1448788–1448798
96Edwards Lifesciences Corporation, Section 10b CEO totalDEF 14A2026-03-260001099800-26-000015CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451
97Bausch Health Companies Inc., Section 10b CEO totalDEF 14A2026-04-080001140361-26-013816CEO total compensation as printed in Bausch Health Companies Inc.'s own proxy. As printed: 16,877,326. Filing ↗machine: r2 · c25 · span 1071578–1071588
98Zimmer Biomet Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-010001193125-26-135661CEO total compensation as printed in Zimmer Biomet Holdings, Inc.'s own proxy. As printed: 16,106,550. Filing ↗machine: t111 · r3 · c16 · span 1895785–1895795
99Hologic, Inc., Section 10b CEO totalDEF 14A2025-01-160001140361-25-001287CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674
100Charles River Laboratories International, Inc., Section 10b CEO totalDEF 14A2026-03-310001104659-26-037367CEO total compensation as printed in Charles River Laboratories International, Inc.'s own proxy. As printed: 15,435,220. Filing ↗machine: r1 · c53 · span 1119658–1119668
101Elanco Animal Health Inc (subject), Section 10b CEO totalDEF 14A2026-04-080001739104-26-000016CEO total compensation as printed in Elanco Animal Health Inc's own proxy. As printed: 14,925,756. Filing ↗machine: r4 · c24 · span 1067844–1067854
102IDEXX Laboratories, Inc., Section 10b CEO totalDEF 14A2026-03-270000874716-26-000064CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018
103Revvity, Inc., Section 10b CEO totalDEF 14A2026-03-160001193125-26-107266CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. Filing ↗machine: span 751285–751295
104Agilent Technologies, Inc., Section 10b CEO totalDEF 14A2026-02-060001193125-26-040286CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992
105STERIS plc, Section 10b CEO totalDEF 14A2026-06-110001193125-26-267599CEO total compensation as printed in STERIS plc's own proxy. As printed: 11,508,522. Filing ↗machine: t172 · r6 · c34 · span 820590–820600
106QuidelOrtho Corporation, Section 10b CEO totalDEF 14A2026-04-270001906324-26-000018CEO total compensation as printed in QuidelOrtho Corporation's own proxy. As printed: 11,255,782. Filing ↗machine: r4 · c24 · span 760612–760622
107Perrigo Company plc, Section 10b CEO totalDEF 14A2026-03-200001585364-26-000024CEO total compensation as printed in Perrigo Company plc's own proxy. As printed: 9,042,603. Filing ↗machine: r3 · c12 · span 2143273–2143282
108DENTSPLY SIRONA Inc., Section 10b CEO totalDEF 14A2026-04-230000818479-26-000125CEO total compensation as printed in DENTSPLY SIRONA Inc.'s own proxy. As printed: 8,760,139. Filing ↗machine: r5 · c27 · span 1201378–1201387
109Catalent, Inc., Section 10b CEO totalDEF 14A2023-12-150001193125-23-295996CEO total compensation as printed in Catalent, Inc.'s own proxy. As printed: 6,583,672. Filing ↗machine: t161 · r3 · c31 · span 1055835–1055844
110Section 10a, Vertex Pharmaceuticals, Inc. reciprocityDEF 14A0000875320-26-000153Vertex Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
111Section 10a, Jazz Pharmaceuticals plc reciprocityDEF 14A0001232524-26-000029Jazz Pharmaceuticals plc's most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
112Section 10a, DENTSPLY SIRONA Inc. reciprocityDEF 14A0000818479-26-000125DENTSPLY SIRONA Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
113Section 10a, IDEXX Laboratories, Inc. reciprocityDEF 14A0000874716-26-000064IDEXX Laboratories, Inc. names Elanco Animal Health Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
114Section 10a, Agilent Technologies, Inc. reciprocityDEF 14A0001193125-26-040286Agilent Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
115Section 10a, Edwards Lifesciences Corporation reciprocityDEF 14A0001099800-26-000015Edwards Lifesciences Corporation's most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
116Section 10a, Zoetis Inc. reciprocityDEF 14A0001555280-26-000015Zoetis Inc. names Elanco Animal Health Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
117Section 10a, STERIS plc reciprocityDEF 14A0001193125-26-267599STERIS plc's most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
118Section 10a, Revvity, Inc. reciprocityDEF 14A0001193125-26-107266Revvity, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
119Section 10a, Zimmer Biomet Holdings, Inc. reciprocityDEF 14A0001193125-26-135661Zimmer Biomet Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
120Section 10a, Catalent, Inc. reciprocityDEF 14A0001193125-23-295996Catalent, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
121Section 10a, Perrigo Company plc reciprocityDEF 14A0001585364-26-000024Perrigo Company plc's most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
122Section 10a, Bausch Health Companies Inc. reciprocityDEF 14A0001140361-26-013816Bausch Health Companies Inc. names Elanco Animal Health Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
123Section 10a, Charles River Laboratories International, Inc. reciprocityDEF 14A0001104659-26-037367Charles River Laboratories International, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
124Section 10a, QuidelOrtho Corporation reciprocityDEF 14A0001906324-26-000018QuidelOrtho Corporation's most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗
125Section 10a, Hologic, Inc. reciprocityDEF 14A0001140361-25-001287Hologic, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗